Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I)

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2024, Volume and Issue: 63(5), P. 637 - 650

Published: Sept. 1, 2024

The WHO (World Health Organization) conducted an elimination of cervical cancer program using triple pillar intervention strategy to target 90%-70%-90% women before the year 2030, including (1) a full vaccination HPV (human papillomavirus) vaccine 90% girls <15 years age; (2) high-performance screening procedure 70% during reproductive age (at 35 and 45 age); (3) appropriate adequate treatment with confirmed diagnosis lesions. Among aforementioned three pillars, has been introduced in our previous review, which we have discussed policy world also reviewed efficacy vaccination, successful reduction over HPV-associated neoplasms. aims current review will another pillar-an Since early-stage favorable outcome recommendation established, therefore, focuses on persistent, recurrent metastatic cancers (advanced cancers), are still biggest challenge based its extremely worse outcomes introduction immune checkpoint inhibitors (ICIs). Integration ICIs into conventional chemotherapy (paclitaxel-cisplatin) become new standard therapy for those patients advanced cancers. recent clinical trials, such as KENOTE 826 A18 showing dramatical improvement both progression free survival overall approved therapeutic this combination ICI plus paclitaxel-platinum (cisplatin or carboplatin) with/without bevacizumab

Language: Английский

---

Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review

Life, Journal Year: 2025, Volume and Issue: 15(2), P. 283 - 283

Published: Feb. 12, 2025

Tumor treatment has undergone revolutionary changes with the development of immunotherapy, especially immune checkpoint inhibitors. Because not all patients respond positively to therapeutic agents, and severe immune-related adverse events (irAEs) are frequently observed, biomarkers evaluating response a patient is key for application immunotherapy in wider range. Recently, various multi-omics features measured by high-throughput technologies, such as tumor mutation burden (TMB), gene expression profiles, DNA methylation have been proved be sensitive accurate predictors immunotherapy. A large number predictive models based on these features, utilizing traditional machine learning or deep frameworks, also proposed. In this review, we aim cover recent advances predicting using features. These include new measurements, research cohorts, data sources, models. Key findings emphasize importance TMB, neoantigens, MSI, mutational signatures ICI responses. The integration bulk single-cell RNA sequencing enhanced our understanding microenvironment enabled identification like PD-L1 IFN-γ signatures. Public datasets improved tools. However, challenges remain, need diverse clinical datasets, standardization data, model interpretability. Future will require collaboration among researchers, clinicians, scientists address issues enhance cancer precision.

Language: Английский

---

Identification and validation of CDK1 as a promising therapeutic target for Eriocitrin in colorectal cancer: a combined bioinformatics and experimental approach

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 13, 2025

Colorectal cancer (CRC) is a prevalent malignancy worldwide, associated with significant morbidity and mortality. Cyclin-dependent kinase 1 (CDK1) plays crucial role in cell cycle regulation has been implicated various cancers. This study aimed to evaluate the prognostic value of CDK1 CRC identify traditional Chinese medicines (TCM) that can target as potential treatments for CRC. The expression were analyzed through TCGA, GEO, GEPIA, UALCAN HPA databases. An ESTIMATE analysis was applied estimate proportions stromal immune cells tumor samples. GO KEGG enrichment analyses performed clarify functional roles CDK1-related genes. CCK-8, colony formation, migration, invasion, wound healing assays employed explore tumor-promoting CDK1. Molecular docking, cellular thermal shift, isothermal dose-response inhibitors highly expressed poorer prognosis. also correlated levels infiltration. genes primarily involved P53 signaling pathway. Knockdown inhibited proliferation, invasion vitro. Furthermore, Eriocitrin emerged inhibitor, exerting its anti-tumor effects by targeting inhibiting activity. critical Eriocitrin, inhibitor derived from TCM, highlights promising new therapeutic strategy treatment.

Language: Английский

---

Leptomeningeal metastasis and cancer immunotherapy

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

LAG Time in the Era of Immunotherapy—New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene‐3

Immunological Reviews, Journal Year: 2025, Volume and Issue: 330(1)

Published: Jan. 31, 2025

The immune checkpoint receptor lymphocyte activation gene-3 (LAG3) inhibits T-cell and was recently validated as a target for cancer immunotherapy. Despite its emergence therapeutic target, lack of molecular-level insight has obscured our understanding the LAG3 immunosuppression mechanism. This review highlights series breakthroughs that have illuminated fundamental aspects molecular biology. Key discoveries include structural insights into interactions with ligands antibodies, mechanistic studies interference (TCR) signaling, development novel therapeutics. A particular focus is placed on structure-function relationships LAG3-targeting drugs, it become apparent several distinct approaches to antagonism are viable. In addition antagonists, agonistic antibodies immunostimulatory extracellular domains (ECDs) discussed in context current data. Collectively, these findings should provide an updated landscape design optimal LAG3-based therapeutics autoimmune diseases.

Language: Английский

---

Research Progress on the Efficacy of Immune Checkpoint Inhibitor Combination Therapy in Advanced Non-Small Cell Lung Cancer

Hans Journal of Biomedicine, Journal Year: 2025, Volume and Issue: 15(02), P. 265 - 272

Published: Jan. 1, 2025

Language: Английский

---

Complete pathological response to neoadjuvant chemoradiotherapy is associated with improved long-term survival after surgical treatment for rectal cancer

Surgical Oncology, Journal Year: 2025, Volume and Issue: unknown, P. 102206 - 102206

Published: March 1, 2025

Language: Английский

---

Classification of lung adenocarcinoma based on senescence-related genes identifies a cluster with immunotherapy resistance and poor prognosis

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: March 20, 2025

Lung adenocarcinoma is one of the major contributors to cancer-related mortality, with immunotherapy emerging as a key treatment. However, many patients exhibit resistance immune checkpoint inhibitors. Cellular senescence has been linked tumor progression and drug resistance, influencing microenvironment. This study applied consensus clustering classify lung into two clusters based on senescence-related gene expression, revealing differing characteristics. One identified exhibited immunosuppressive characteristics showed immunotherapy. A risk score was developed using machine learning predict response prognosis. High correlated poorer survival increased across multiple cancer types. The model robust predictive ability in both training validation cohorts. These findings suggest link between further investigation their relationship could reveal new perspectives for

Language: Английский

---

Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management

The EPMA Journal, Journal Year: 2025, Volume and Issue: unknown

Published: March 22, 2025

Language: Английский

---

The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy

Journal of Inflammation Research, Journal Year: 2025, Volume and Issue: Volume 18, P. 4335 - 4357

Published: March 1, 2025

Monoclonal antibodies (mAbs) have transformed cancer treatment by providing highly targeted and effective therapies that specifically attack cells, thus reducing the likelihood of adverse events (AEs) in patients. mAbs exert their action through various mechanisms, such as receptor blockade, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent (CDC), inhibition immune checkpoints (eg, PD-1, PD-L1, CTLA-4). These led to significant improvements several cancers, including HER2-positive breast cancer, non-small cell lung (NSCLC), melanoma. The efficacy mAb therapy is influenced intrinsic extrinsic factors, environmental exposures, psychosocial infection status, ways life, tumor microenvironment (TME), all which can impact responses outcomes. Notably, therapeutic benefits are often accompanied immune-related AEs (irAEs), vary from mild severe affect multiple organ systems. dual nature mAbs-stimulating antitumor while also inducing side effects-presents a notable challenge clinical practice. This review highlights importance proactive strategies for managing irAEs, early detection, corticosteroid use, immunosuppressive treatments, urgent need reliable predictive biomarkers improve Advancements prevention, prediction, management irAEs essential enhance safety effectiveness mAb-based therapies, ultimately aiming patient

Language: Английский

---